The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial

Omid Toupchian; Shima Abdollahi; Amin Salehi-Abargouei; Javad Heshmati; Cain C T Clark; Mohammad Hasan Sheikhha; Hossein Fallahzadeh; Hassan Mozaffari-Khosravi

doi:10.1002/ptr.7031

The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial

Omid Toupchian, Shima Abdollahi, Amin Salehi-Abargouei, Javad Heshmati, Cain C T Clark, Mohammad Hasan Sheikhha, Hossein Fallahzadeh, Hassan Mozaffari-Khosravi

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

156 Downloads (Pure)

Abstract

The present study sought to evaluate the effect of resveratrol supplementation on mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARα), p53, p21, p16, and serum levels of cluster of differentiation 163 (CD163) to TNF-like weak inducer of apoptosis (TWEAK) ratio in patients with type 2 diabetes. In this double-blind randomized controlled trial, 71 patients were randomly assigned to receive either 1,000 mg of trans-resveratrol or placebo (methyl cellulose) for 8 weeks. Expression levels of genes of interest, and serum levels of sCD163 and sTWEAK were assessed at baseline and at the end of the study. Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006). However, no significant effect on expression levels of PPARα and p16 genes was observed after supplementation. In addition, resveratrol significantly reduced serum levels of sCD163/sTWEAK ratio compared with the placebo group (p = .003). Resveratrol supplementation resulted in significant changes in p53 and p21 genes expression, while serum levels of sCD163/sTWEAK ratio also improved in the resveratrol group, without any significant change in adjusted sCD163 levels. More research is needed to confirm the beneficial effects of resveratrol for patients with diabetes.

Original language	English
Pages (from-to)	3205-3213
Number of pages	9
Journal	Phytotherapy Research
Volume	35
Issue number	6
Early online date	13 Feb 2021
DOIs	https://doi.org/10.1002/ptr.7031
Publication status	Published - Jun 2021

Bibliographical note

This is the peer reviewed version of the following article: Toupchian, O, Abdollahi, S, Salehi-Abargouei, A, Heshmati, J, Clark, CCT, Sheikhha, MH, Fallahzadeh, H & Mozaffari-Khosravi, H 2021, 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial', Phytotherapy Research, vol. 35, no. 6, pp. 3205-3213, which has been published in final form at https://dx.doi.org/10.1002/ptr.7031. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

Funder

Shahid Sadoughi University of Medical Sciences (grant no: 4694) and Iran's National Science Foundation (INSF) (grant no: 96010660),.

Keywords

cardiovascular diseases
resveratrol
sCD163
sTWEAK
type 2 diabetes mellitus

ASJC Scopus subject areas

Pharmacology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/ptr.7031

Post-PrintAccepted author manuscript, 1.47 MB

Cite this

Toupchian, O., Abdollahi, S., Salehi-Abargouei, A., Heshmati, J., Clark, C. C. T., Sheikhha, M. H., Fallahzadeh, H., & Mozaffari-Khosravi, H. (2021). The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial. Phytotherapy Research, 35(6), 3205-3213. https://doi.org/10.1002/ptr.7031

The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial. / Toupchian, Omid; Abdollahi, Shima; Salehi-Abargouei, Amin et al.
In: Phytotherapy Research, Vol. 35, No. 6, 06.2021, p. 3205-3213.

Research output: Contribution to journal › Article › peer-review

Toupchian, O, Abdollahi, S, Salehi-Abargouei, A, Heshmati, J, Clark, CCT, Sheikhha, MH, Fallahzadeh, H & Mozaffari-Khosravi, H 2021, 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial', Phytotherapy Research, vol. 35, no. 6, pp. 3205-3213. https://doi.org/10.1002/ptr.7031

Toupchian O, Abdollahi S, Salehi-Abargouei A, Heshmati J, Clark CCT, Sheikhha MH et al. The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial. Phytotherapy Research. 2021 Jun;35(6):3205-3213. Epub 2021 Feb 13. doi: 10.1002/ptr.7031

@article{14e78cc792a249a294ea6aa6a0be9ecd,

title = "The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial",

abstract = "The present study sought to evaluate the effect of resveratrol supplementation on mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARα), p53, p21, p16, and serum levels of cluster of differentiation 163 (CD163) to TNF-like weak inducer of apoptosis (TWEAK) ratio in patients with type 2 diabetes. In this double-blind randomized controlled trial, 71 patients were randomly assigned to receive either 1,000 mg of trans-resveratrol or placebo (methyl cellulose) for 8 weeks. Expression levels of genes of interest, and serum levels of sCD163 and sTWEAK were assessed at baseline and at the end of the study. Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006). However, no significant effect on expression levels of PPARα and p16 genes was observed after supplementation. In addition, resveratrol significantly reduced serum levels of sCD163/sTWEAK ratio compared with the placebo group (p = .003). Resveratrol supplementation resulted in significant changes in p53 and p21 genes expression, while serum levels of sCD163/sTWEAK ratio also improved in the resveratrol group, without any significant change in adjusted sCD163 levels. More research is needed to confirm the beneficial effects of resveratrol for patients with diabetes.",

keywords = "cardiovascular diseases, resveratrol, sCD163, sTWEAK, type 2 diabetes mellitus",

author = "Omid Toupchian and Shima Abdollahi and Amin Salehi-Abargouei and Javad Heshmati and Clark, {Cain C T} and Sheikhha, {Mohammad Hasan} and Hossein Fallahzadeh and Hassan Mozaffari-Khosravi",

note = "This is the peer reviewed version of the following article: Toupchian, O, Abdollahi, S, Salehi-Abargouei, A, Heshmati, J, Clark, CCT, Sheikhha, MH, Fallahzadeh, H & Mozaffari-Khosravi, H 2021, 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial', Phytotherapy Research, vol. 35, no. 6, pp. 3205-3213, which has been published in final form at https://dx.doi.org/10.1002/ptr.7031. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Copyright {\textcopyright} and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders. ",

year = "2021",

month = jun,

doi = "10.1002/ptr.7031",

language = "English",

volume = "35",

pages = "3205--3213",

journal = "Phytotherapy Research",

issn = "0951-418X",

publisher = "Wiley",

number = "6",

}

TY - JOUR

T1 - The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus

T2 - A double-blind controlled randomized trial

AU - Toupchian, Omid

AU - Abdollahi, Shima

AU - Salehi-Abargouei, Amin

AU - Heshmati, Javad

AU - Clark, Cain C T

AU - Sheikhha, Mohammad Hasan

AU - Fallahzadeh, Hossein

AU - Mozaffari-Khosravi, Hassan

N1 - This is the peer reviewed version of the following article: Toupchian, O, Abdollahi, S, Salehi-Abargouei, A, Heshmati, J, Clark, CCT, Sheikhha, MH, Fallahzadeh, H & Mozaffari-Khosravi, H 2021, 'The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial', Phytotherapy Research, vol. 35, no. 6, pp. 3205-3213, which has been published in final form at https://dx.doi.org/10.1002/ptr.7031. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.

PY - 2021/6

Y1 - 2021/6

N2 - The present study sought to evaluate the effect of resveratrol supplementation on mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARα), p53, p21, p16, and serum levels of cluster of differentiation 163 (CD163) to TNF-like weak inducer of apoptosis (TWEAK) ratio in patients with type 2 diabetes. In this double-blind randomized controlled trial, 71 patients were randomly assigned to receive either 1,000 mg of trans-resveratrol or placebo (methyl cellulose) for 8 weeks. Expression levels of genes of interest, and serum levels of sCD163 and sTWEAK were assessed at baseline and at the end of the study. Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006). However, no significant effect on expression levels of PPARα and p16 genes was observed after supplementation. In addition, resveratrol significantly reduced serum levels of sCD163/sTWEAK ratio compared with the placebo group (p = .003). Resveratrol supplementation resulted in significant changes in p53 and p21 genes expression, while serum levels of sCD163/sTWEAK ratio also improved in the resveratrol group, without any significant change in adjusted sCD163 levels. More research is needed to confirm the beneficial effects of resveratrol for patients with diabetes.

AB - The present study sought to evaluate the effect of resveratrol supplementation on mRNA expression levels of peroxisome proliferator-activated receptor alpha (PPARα), p53, p21, p16, and serum levels of cluster of differentiation 163 (CD163) to TNF-like weak inducer of apoptosis (TWEAK) ratio in patients with type 2 diabetes. In this double-blind randomized controlled trial, 71 patients were randomly assigned to receive either 1,000 mg of trans-resveratrol or placebo (methyl cellulose) for 8 weeks. Expression levels of genes of interest, and serum levels of sCD163 and sTWEAK were assessed at baseline and at the end of the study. Resveratrol supplementation significantly increased mRNA expression levels of p53 and p21 genes, compared with the placebo group (fold change of p53 = 1.29, p = .04; fold change of p21 = 1.46, p = .006). However, no significant effect on expression levels of PPARα and p16 genes was observed after supplementation. In addition, resveratrol significantly reduced serum levels of sCD163/sTWEAK ratio compared with the placebo group (p = .003). Resveratrol supplementation resulted in significant changes in p53 and p21 genes expression, while serum levels of sCD163/sTWEAK ratio also improved in the resveratrol group, without any significant change in adjusted sCD163 levels. More research is needed to confirm the beneficial effects of resveratrol for patients with diabetes.

KW - cardiovascular diseases

KW - resveratrol

KW - sCD163

KW - sTWEAK

KW - type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85100851523&partnerID=8YFLogxK

U2 - 10.1002/ptr.7031

DO - 10.1002/ptr.7031

M3 - Article

C2 - 33580595

SN - 0951-418X

VL - 35

SP - 3205

EP - 3213

JO - Phytotherapy Research

JF - Phytotherapy Research

IS - 6

ER -

The effects of resveratrol supplementation on PPARα, p16, p53, p21 gene expressions, and sCD163/sTWEAK ratio in patients with type 2 diabetes mellitus: A double-blind controlled randomized trial

Abstract

Bibliographical note

Funder

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this